Skip to main content
Erschienen in: BMC Cardiovascular Disorders 1/2018

Open Access 01.12.2018 | Research article

Comparison of outcomes in emergency department patients with suspected cardiac chest pain: two-centre prospective observational study in Southern China

verfasst von: Huilin Jiang, Yunmei Li, Junrong Mo, Xiaohui Chen, Min Li, Peiyi Lin, Kevin K. C. Hung, Timothy H. Rainer, Colin A. Graham

Erschienen in: BMC Cardiovascular Disorders | Ausgabe 1/2018

Abstract

Background

Hong Kong (HK) and Guangzhou (GZ) are cities in China with different healthcare systems. This study aimed to compare 30-day and 6-month mortality and characteristics of patients with suspected cardiac chest pain admitted to two emergency departments (ED) in HK and GZ.

Methods

A prospective observational study enrolled patients with suspected cardiac chest pain presenting to EDs in the Prince of Wales Hospital (PWH), HK and the Second Affiliated Hospital of Guangzhou Medical University (AHGZMU),GZ. The primary outcome was 30-day and 6-month mortality.

Results

In total, 996 patients were recruited, 407 cases from GZ and 589 cases from HK.The 30-day and 6-month mortality of chest patients were 3.7% and 4.7% in GZand 0.3% and 1.9% in HK, respectively. Serum creatinine level (Cr) was an independent factor for 30-day mortality whilst Cr and systolic blood pressure (SBP) were independent factors for 6-month mortality. In Cox regression analysis, unadjusted and adjusted hazard ratios for 30-day and 6-month mortality in GZ were significantly increased.

Conclusion

The 30-day and 6-month mortality of patients with suspected cardiac chest pain in Guangzhou were higher than in Hong Kong due to due to different baseline clinical characteristics of patients and different distributions of diagnoses, which were associated with different healthcare systems. Serum creatinine and SBP were independent factors for 30-day and 6-month mortality.
Begleitmaterial
Additional file 1: Definition of HEART score [29]: There were five elements: history, ECG, age,risk factors and troponin in HEART score. Each variable was scored as 0, 1 or 2 points. Each patient will receive a score of 1-10. (DOCX 32 kb)
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12872-018-0814-4) contains supplementary material, which is available to authorized users.
Abkürzungen
ACS
Acute coronary syndrome
AHGZMU
The Second Affiliated Hospital of Guangzhou Medical University
CABG
Coronary artery bypass grafting
CAD
Coronary artery disease
CK
Creatine Kinase
CK-MB
Creatine Kinase Isoenzyme-MB
CMS
Clinical Management System
cTnT
Cardiac troponin T
ED
Emergency department
GZ
Guangzhou
HK
HongKong
IQR
Interquartile range
MACE
Major adverse cardiac events
NSTEMI
Non ST-segment elevation myocardial infarction
PPCI
Primary percutaneous coronary intervention
PWH
Prince of Wales Hospital
STEMI
ST elevation myocardial infarction
US
United States

Backgroud

Chest pain is a common chief complaint of patients presenting to emergency departments (ED) globally, and it places a huge burden on ED services [13]. The challenge for clinicians is the dual danger of discharging patients at potential high risk and the clinical pressure of EDs crowded with low risk patients. In order to improve the quality of care and survival rates of cardiac patients, there is a worldwide impetus to develop and improve systems for emergency cardiac care [4]. Current guidelines emphasize rapid determination of the likelihood that the patient’s clinical presentation represents high risk chest pain, such as acute coronaryartery disease, and rapid assessment of the immediate risk for a major adverse cardiac event (MACE) [5]. Hong Kong (HK) and Guangzhou (GZ) are cities in southern China with almost the same ethnicity but different healthcare systems [6]. The healthcare system of HK has adopted health care financing and organizational health systems that are commonly seen in centrally planned economies. In contrast, mainland China has integrated many features of health care systems associated with market economies, whereas both have advanced systems of chest pain care in EDs [79]. So the healthcare systems of the two cities are quite different under the “one country, two systems” policy [10]. No study has compared clinical outcomes of susceptive cardiac chest pain patients with similar ethnicity under different healthcare systems, and the influence factor of its outcome. Our previous study has compared the clinical ED management and one-year mortality of ST-segment elevation myocardial infarction (STEMI) patients between the two hospitals in HK and GZ [11]. After that, the comparable registries of chest pain database have been developed in Guangzhou and Hong Kong. The objective of the study was to compare 30-day and 6-month outcomes of patients with suspected cardiac chest pain presenting to two EDs in HK and GZ, and contributory factors of outcomes.

Methods

Study design and setting

A prospective cohort study conducted from May 2012 to August 2013 in two teaching hospitals.
The Second Affiliated Hospital of Guangzhou Medical University (AHGZMU)is an academic hospital with 1500 beds affiliated with the Guangzhou Medical University and serves a population of approximately 1.56 million people in the Hai Zhu district, Guangzhou. The ED receives more than 150,000 new patients per annum and serves a local population of approximately 1,680,000 people. The Prince of Wales Hospital (PWH) is located in the New Territories in Hong Kong. It is a university hospital with 1400 beds. It sees approximately 150,000 new ED patients per annum and serves a local population of approximately 800,000 people.

Inclusion and exclusion criteria

Consecutive ED patient ≥18 years old, with a chief complaint of chest pain or discomfort were recruited. Patients were excluded if they clearly had a non-cardiac cause of chest pain. Confirmed STEMI patients at ED presentation were also excluded as they did not have undifferentiated chest pain. Patients were excluded if they were unable or unwilling to provide informed consent or unable to be contacted after discharge.

Measurements and data collection

Baseline patient characteristics, the characteristics of the chest pain (such as location, feature and radiation), vital signs, medical history, family history of coronary artery disease (CAD), ECG results and contact information to facilitate subsequent follow-up were collected and recorded in a computerized database. The HEART score was recorded and calculated by research staff. The details of the HEART score are shown in Additional file 1. Guidelines recommend that patients with possible ACS but with a normal initial ECG and cardiac markers should be observed in a chest pain unit, where continuous cardiac monitoring and repeated measurement of cardiac markers is available [12]. Point-of care troponin testswere used in GZ, whilst high sensitivity troponin tests were used in HK. Therefore, the results of troponin were divided into four groups (≤1× normal range, 1×-2× normal range, 2×-3× normal range and ≥ 3× normal range) for analysis. ST-depression on initialECG means ST depression ≥1.0mv in any lead of the initial ECG. The onset-ED time and ED-ECG time were recorded. Follow-up data were obtained from the Clinical Management System (CMS) in HK and Health Insurance Information Management System (HIIMS) in GZ.

Follow up

Subsequent visits to ED, hospital readmission for evaluation of chest pain and all cardiac procedures performed were retrieved from CMS in HK and HIIMS in GZ, and verified via telephone at 30-days and 6-months follow-up after initial presentation. Furthermore, death, myocardial infarction, readmission for ACS, and all cardiac testing and coronary revascularization procedures were also obtained via CMS and HIIMS.

Sample size calculation

According to our previous study [7], the 30-day MACE rates in Chinese patients presenting to ED with cardiac chest pain could have been as high as the upper limit of the 95% confidence interval in the low-risk group i.e. 13%, and as low as the lower limit of the 95% confidence interval in the high-risk group i.e. 23%. To achieve adequate power to address the objectives by using 2-tailed alpha of 0.05 and a power of 80%, the minimum sample size required per group is 220. We aimed to recruit an extra 30% in case of unforeseen circumstances and thus at least 230 (230 × 1.3 = 299) patients were required per group. Therefore, the minimum sample size in this study was 598 (299 × 2 recruiting sites = 598).

Outcomes

The primary outcomefor each patient wasall cause mortality within 30 days and 6 monthsafter initial ED presentation. The secondary outcomes were the contributory factors of primary outcomes.

Statistical analyses

Continuous variables were presented as median and interquartile range or mean ± standard deviation as appropriate. Categorical variables were expressed as frequencies. Statistical analysis was performed using SPSS v17.0 (SPSS Inc., IL, USA) and Medcalc v9.5 (MedCalc Software, Mariakerke, Belgium). Summary statistics were used to describe patient characteristics from the Hong Kong and Guangzhou groups. Chi-square analysis was used for categorical variables, whilst independent t-tests or Mann-Whitney U-tests were used for comparing data from continuous variables. An initial univariate analysis was performed on all variables with 30-day and 6-month mortalityas the dependent variables and presented as unadjusted odds ratios (OR) and 95% confidence intervals (95% CI). Variables with p ≤ 0.1 were entered into a multivariate ordinal logistic regression. Cumulative survival curves in relation to different hospitals were determined according to the Kaplan-Meier method with the use of log-rank tests for statistical assessment. Cox regression analysis was used to calculate unadjusted and adjusted hazard ratios (HRs) and 95% CIs for mortality rates after 30 days and 6 months in relation to different hospitals. A P value of < 0.05 was considered statistically significant and all probabilities were two tailed.

Results

Recruitment of patients from the two centers

Patients were recruited from 17 March 2012 to 14 August 2013. The flow chart of the patient recruitment was shown in Fig. 1. There were 1025 eligible patients, with 589 cases in HK and 436 cases in GZ. Twenty-nine patients were excluded due to lack of follow-up data, leaving 996 patients (407 cases from GZ and 589 cases from HK) in the study. The mean age of the 996 patients was 65.1 ± 14.5 years and 55.3% were males.

Baseline characteristics and final diagnoses of chest pain patients

Table 1 shows the characteristics of chest pain patients from GZ and HK. Compared to patients in HK, patients in GZ were older and had lower proportions of past history of diabetes, hyperlipidaemia and chronic heart failure, lower proportion of NHYA class I and lower blood pressure. Troponin is a key biomarker to detect myocardial injury in the two hospitals. Troponin was used as a myocardial injury biomarker in 98% patients in HK and 70% patients in GZ. Creatine kinase (CK) and creatine kinase isoenzyme-MB (CK-MB) were the predominant biomarkers used in GZ, in which 98% patients had a CK level determined. However, these tests were rarely used in HK. Ischaemic cardiac chest pain was diagnosed in 120 (29.4%) patients in GZ (9.8% with NSTEMI, 16.0% with unstable angina and 3.7% with stable angina). Non-ischaemic cardiac aetiologies and non-cardiac aetiologies were found in 136 (33.4%) and 151 (37.1%) patients respectively. In HK, 163 (27.7%) patients had ischaemic cardiac chest pain, including 5.4% with NSTEMI, 12.1% with unstable angina and 10.2% with stable angina. 84 (14.3%) patients were diagnosed as having non-ischaemic cardiac aetiologies and 342 (58.1%) were diagnosed with non-cardiac aetiologies. There were significant differences in the number of cases diagnosed with non-ischaemic cardiac aetiologies and non-cardiac chest pain between GZ and HK (P < 0.0001), whilst there was no significant difference in the number of cases diagnosed with ischaemic cardiac chest pain between the two hospitals.There were no significant differences in the number of readmission of 30-day and 6-month.
Table 1
Comparison of patient characteristics between the two hospitals (N = 996)
 
AHGZMU (n = 407)
PWH (n = 589)
P
Age, years, mean (SD)
66.6 (14.4)
63.7 (14.6)
0.002*
Males, n (%)
220 (54.1)
325 (55.2)
0.726
Past histories
 Smoker, n (%)
69 (17.0)
78 (13.2)
0.105
 Hypertension, n (%)
245 (60.2)
362 (60.9)
0.688
 Diabetes, n (%)
79 (19.4)
153 (26.0)
0.016*
 Hyperlipidemia, n (%)
92 (22.6)
266 (45.2)
< 0.0001*
 Chronic heart failure, n (%)
26 (6.4)
62 (10.5)
0.024*
 Family heart disease, n (%)
72 (17.7)
125 (21.2)
0.169
 Stroke, n (%)
26 (6.4)
72 (12.2)
0.002*
 Peripheral arterial disease, n (%)
6 (1.5)
20 (3.4)
0.062
NHYA classification
 NHYA class I, n (%)
234 (57.5)
401 (68.1)
0.001*
 NHYA class II, n (%)
118 (29.0)
75 (12.7)
< 0.0001
 NHYA class III, n (%)
51 (12.5)
108 (18.3)
0.014*
 NHYA class IV, n (%)
4 (1.0)
5 (0.8)
0.826
First ED characteristics
 Heart rate, bpm, mean (SD)
88.4 (27.8)
82.0 (19.1)
< 0.0001*
 Systolic blood pressure, mmHg, mean (SD)
141.3 (30.1)
148.7 (25.9)
0.001*
 Diastolic blood pressure, mmHg, mean (SD)
78.2 (17.0)
80.1 (15.4)
0.018
First lab results in ED
 Creatinine, μmoL/L, median (IQR)
88.0 (71.0, 109.0)
81.0 (66.0, 97.0)
< 0.0001*
 Troponin
   ≤ 1×
224 (78.9)
420 (72.4)
< 0.0001*
  1×-2×
21 (7.4)
85 (14.7)
< 0.0001*
  2×-3×
8 (2.8)
22 (3.8)
0.108
   ≥ 3×
31 (10.9)
53 (9.1)
0.441
 Number of CK done, n (%)
399 (98.0)
339 (57.6)
< 0.0001*
 Number of CK-MB done, n (%)
399 (98.0)
0 (0)
< 0.0001*
ST segment depression, n (%)
80 (8.0)
19 (1.9)
< 0.0001*
Onset- ED time,hour, median (IQR)
4.03 (1.5–13.21)
6.52 (2.01–23.27)
< 0.0001*
ED-ECG time, hour, median (IQR)
0.17 (0.03–0.47)
0.18 (0.12–0.28)
0.234
HEART Score, median (IQR)
4 (3,6)
4 (2,5)
< 0.0001*
Number of admission
231 (56.8)
334 (56.7)
0.987
Final diagnoses
 Ischemia coronary chest pain
120 (29.5)
163 (27.7)
0.534
  NSTEMI, n (%)
40 (9.8)
32 (5.4)
 
  Unstable angina, n (%)
65(16.0)
71(12.1)
 
  Stable angina, n (%)
15 (3.7)
60 (10.2)
 
 Non-ischaemia cardiac chest pain, n (%)
136 (33.4)
84 (14.3)
< 0.0001*
 Non-cardiac chest pain, n (%)
151 (37.1)
342 (58.1)
< 0.0001*
*statistically significant

Comparison of clinical outcomes of chest pain patients in the two centres

Table 2 shows the 30-day and 6-month mortality of chest painpatients. The 30-day mortality rates for ischaemia, non-ischaemic cardiac and non-cardiac causes in GZwere 1.5%, 1.0% and 1.7% respectively. No one died of ischaemia and non-ischaemia cardiac aetiologies in HK up to 30-days follow-up. The 30-day mortality rates for non-cardiac causes was 0.7% in HK. The 6-month mortality rates of ischaemic chest painin GZ were statistically higher than those in HK.
Table 2
Comparison of 30-day and 6-month mortality in patients with different diagnoses between the two hospitals (N = 996)
 
30-day mortality in GZ (n = 407)
30-day mortality in HK (n = 589)
P
6-month mortality in GZ (n = 407)
6-month mortality in HK (n = 589)
P
Final diagnoses
 Ischemia coronary chest pain
6 (1.5)
0 (0)
0.005*
7 (1.7)
2 (0.3)
0.036*
  NSTEMI, n (%)
4 (1.0)
0 (0)
 
5 (1.2)
1 (0.2)
 
  Unstable angina, n (%)
2 (0.5)
0 (0)
 
2 (0.5)
0 (0)
 
  Stable angina, n (%)
0 (0)
0 (0)
 
0 (0)
1 (0.2)
 
 Non-ischaemia cardiac causes, n (%)
4 (1.0)
0 (0)
0.28
5 (1.2)
3 (0.5)
0.283
 Non-cardiac causes, n (%)
5 (1.2)
2 (0.3)
0.129
7 (1.7)
6 (1.0)
0.339
Total
15 (3.7)
2 (0.3)
< 0.0001*
19 (4.7)
11 (1.9)
0.011
The death reasons of non-cardiac chest pain were: pulmonary embolism = 1 in GZ, pneumonia = 1in GZ and 3 in HK, ischaemic stroke = 1 in GZ, cancer = 1 in GZ and 3 in HK, other reasons = 3 in GZ
The death reasons of non-ischaemic cardiac chest pain were: heart failure = 2in GZ and 2 in HK, Valvular heart disease = 1 in HK, Aortic dissection = 3 in GZ
*statistically significant
The 6-month mortality of ischemia, non-ischaemic cardiac and non-cardiac causes in GZ were 1.7%, 1.2% and 1.7% respectively, whilst in HK these were 0.3%, 0.5% and 1.0% respectively. NSTEMI patients demonstrated a higher mortality than other ischaemic chest pain patients at 30-day and 6-month follow-up. Compared with cardiac aetiologies, higher mortality was observed for non-cardiac causes. Most diagnoses of non-cardiac chest pain were pulmonary embolism, pneumonia, ischemia stroke and cancer (see Table 2 for details).

Univariate and multivariate logistic regression for 30-day and 6-month mortality

Table 3 shows patients were more likely to die after 30 days if they were older, had ST-segment deviation, a history of worse NHYA class and lower SBP and DBP, higher serum creatinine and troponin level at ED admission, and a higher HEART score. After multivariate logistic regression, serum creatinine level was the only independent predictor of 30-day mortality.
Table 3
Univariate and multivariate logistic regression for 30-day mortality (N = 996)
 
Unadjusted Odds Ratio (95% CI)
P
Adjusted Odds Ratio (95% CI)
P
Age, years
1.069 (1.023–1.117)
0.003*
1.031 (0.977-1.089)
0.262
Males (vs Females)
2.008 (0.702–5.744)
0.193
  
Past histories
 Smoker (vs non smoker)
2.256 (0.644–7.905)
0.204
  
 Hypertension (vs non hypertension)
1.094 (0.413–2.899)
0.857
  
 Diabetes (vs non diabetes)
0.702 (0.2–2.464)
0.58
  
 Hyperlipidemia (vs non hyperlipidemia)
    
 CHF (vs non CHF)
2.254 (0.635–7.998)
0.209
  
 FHD (vs non FHD)
1.153 (0.328–4.053)
0.824
  
 Stroke (vs non stroke)
0.568 (0.075–4.332)
0.586
  
 PAD (vs non PAD)
    
First ED characteristics
 Heart rate
1.003 (0.982–1.024)
0.804
  
 SBP
0.980 (0.962–0.990)
0.044*
0.990 (0.963-1.089)
0.486
 DBP
0.973 (0.942–1.005)
0.1
1.02 (0.97–1.072)
0.435
NHYA class III, IV (vs NHYA class I,II)
3.557 (1.334–9.481)
0.011*
1.554 (0.405-5.972)
0.521
Troponin Elevation ≥2× (vs < 2×)
10.385 (1.228–87.874)
0.032*
2.471 (0.613-9.955)
0.203
Creatinine elevation (vs normal)
11.643 (3.947–34.347)
< 0.0001*
9.189 (2.319-36.407)
0.002*
ST segment depression (vs normal)
0.175 (0.061–0.5)
0.001*
1.026 (0.973-1.083)
0.34
HEART Score
1.622 (1.228–2.143)
0.001*
0.706 (0.404-1.231)
0.22
Onset- ED time
0.966 (0.919–1.015)
0.172
  
ED-ECG time
1 (1–1)
0.949
  
CHF Chronic heart failure, FHD Family history of heart disease PAD Peripheral arterial disease, SBP Systolic blood pressure, DBP Diastolic blood pressure
Adjusted for age, SBP, DBP,ST segment depression, NHYA classification, troponin, HEART score and serum creatinine
*statistically significant
Table 4 shows patients were more likely to die by 6 months if they were older, had ST-segment depression, a history of chronic heart failure, hyperlipidemia and worse NHYA class, lower SBP, higher serum creatinine and troponin level at ED admission, and higher HEART score. After multivariate logistic regression, serum creatinine level and SBP were the only independent predictors of 6-month mortality.
Table 4
Univariate and multivariate logistic regression for 6-month mortality (N = 996)
 
Unadjusted Odds Ratio (95% CI)
P
Adjusted Odds Ratio (95% CI)
P
Age, years
1.074 (1.038–1.112)
< 0.0001*
1.033 (0.98-1.088)
0.233
Males (vs Females)
0.508 (0.230–1.121)
0.093
0.592 (0.17–2.053)
0.592
Past histories
 Smoker (vs non smoker)
0.755 (0.332–1.715)
0.502
  
 Hypertension (vs non hypertension)
1.291 (0.598–2.789)
0.515
  
 Diabetes (vs non diabetes)
1.002 (0.425–2.367)
0.996
  
 Hyperlipidemia (vs non hyperlipidemia)
0.191 (0.058–0.635)
0.007*
0.00 (0.00-0.00)
0.996
 CHF (vs non CHF)
4.812 (2.132–10.861)
< 0.0001*
3.454 (0.705-16.93)
0.126
 FHD, (vs non FHD)
0.442 (0.133–1.473)
0.184
  
 Stroke (vs non stroke)
1.019 (0.303–1.473)
0.976
  
 PAD (vs non PAD)
1.298 (.170–9.909)
0.801
  
First ED characteristics
 Heart rate
1.007 (0.993–1.022)
0.318
  
 SBP
0.979 (0.965–0.993)
0.004*
0.974 (0.95-0.999)
0.045*
 DBP
0.977 (0.954-1.001)
0.061
1.045 (0.998–1.094)
0.114
NHYA class III, IV (vs NHYA class I,II)
5.314 (2.545–11.095)
< 0.0001*
2.519 (0.685-9.266)
0.165
Troponin Elevation ≥ 2× (vs < 2×)
8.04 (1.693–38.185)
0.009*
2.983 (0.494-18.01)
0.233
Creatinine elevation (vs normal)
11.137 (4.23–29.326)
< 0.0001*
7.48 (2.042-27.369)
0.002*
ST segment depression (vs normal)
4.190 (1.968–8.917)
< 0.0001*
1.006 (0.954-1.061)
0.815
HEART Score
1.603 (1.310–2.027)
< 0.0001*
0.81(0.487-1.349)
0.418
Onset- ED time
0.986 (0.964–1.008)
0.216
  
ED-ECG time
1.00 (1.000–1.000)
0.922
  
CHF Chronic heart failure, FHD Family history of heart disease, PAD Peripheral arterial disease, SBP Systolic blood pressure, DBP Diastolic blood pressure
Adjusted for age, gender, hyperlipidemia, CHF, SBP, DBP, ST segment depression, NHYA classification, troponin, HEART score and serum creatinine
*statistically significant

Survival analysis in two hospitals

Figure 2 showed the corresponding Kaplan-Meier event-free survival curves for different hospitals. Kaplan-Meier analysis demonstrated a significantly increased probability of death ofchest pain patients in GZ after 30 days and 6 months (P < 0.0001 for 30-day mortality using the log-rank test, and P = 0.010 for 6-month mortality using the log-rank test).
In Cox regression analysis, the unadjusted HR for 30-day (HR = 11.05, 95% CI 2.53 to 48.32, P = 0.001) and 6-month (HR = 2.55, 95% CI 1.22 to 5.37, P = 0.013) mortality in GZ was significantly higher (Table 5). After adjusting for age, SBP, ST segment depression, NHYA classification, troponin, HEART score and serum creatinine, the adjusted HR for 30-day (HR = 8.98, 95% CI 1.78 to 45.2, P = 0.008) mortality in GZ was still significantly higher.
Table 5
Unadjusted and adjusted hazard ratios of all-cause mortality at 30-days and 6-months in the two hospitals
 
HR(95% CI)
P
Adjusted HR (95% CI)
P
30-day all-cause mortality
 GZ
11.05 (2.53–48.32)
0.001*
8.98 (1.78-45.2)
0.008*
 HK
Reference
 
Reference
 
6-month all-cause mortality
 GZ
2.55 (1.22–5.37)
0.013*
1.77 (0.73-4.26)
0.205
 HK
Reference
 
Reference
 
30-day mortality was adjusted for age, SBP, DBP, ST segment depression, NHYA classification, troponin, HEART score and serum creatinine
6-month mortality was adjusted for age, gender, hyperlipidemia, CHF, SBP, DBP, ST segment depression, NHYA classification, troponin, HEART score and serum creatinine
*statistically significant
After adjusting for age, hyperlipidemia, CHF, SBP, ST segment depression, NHYA classification, troponin, HEART score and serum creatinine, the adjusted HR for 6-month (HR = 1.77, 95% CI 0.73 to 4.26, P = 0.205) mortality in GZ was not significantly higher than that in HK.

Discussion

This is the first prospective cohort study to compare 30-day and 6-month mortality of suspected cardiac chest pain patients admitted to EDs between two teaching hospitals located in two different cities in southern China with similar ethnicity but differenthealthcare systems [11]. The chest pain patients in GZ had a higher 30-day and 6-month mortalitythan in HK. The findings suggest that the different outcomes were associated with the varying clinical characteristics of patients and different distributions of diagnoses under two differenthealthcare systems. GZ has integrated many features of healthcare system associated with market economies, while its overall economy is largely centrally planned. In contrast,Hong Kong adopt thehealthcare system are come from England and organizational health systems that are commonly seen in centrally planned economies, while its economy functions as a highly capitalisticenterprise [10, 13].

Different distributions of chest pain patients between two hospitals

Over 50% of patients were diagnosed as non-cardiac chest pain in HK, a much higher rate than in GZ (37.1%). This may reflect the different healthcare systems. In Guangzhou, chest pain patients at low risk often present to clinics instead of EDs during office hours. The ED is the only choice for patients with chest pain in HK due to lower medical costs. So, the patients with urgent and severe chest pain/symptoms would likely to present to EDs in GZ. Compared to other studies, the proportion of non-cardiac chest pain patientsin this study was low. The proportions in GZ and HK were 50% and 37.1% respectively compared to 67.2%–70% in other studies [1416]. A lower proportion of non-cardiac chest pain patients may allow earlier discharge from the ED and place less stress on ED and hospital services.
There were no significant differences in 30-day and 6-month mortality for non-ischemic cardiac chest pain and non-cardiac chest pain between the two hospitals. However, there was significantly higher 30-day and 6-month mortality rates for ischemic cardiac chest pain patients in GZ. ACS is a high-risk disease with significant mortality [9, 17]. The current study excluded STEMI patients but NSTEMI and UA patients were recruited. The combined proportion of NSTEMI and UA in GZ was 25.8%, which was higher than thatin HK (17.5%). The proportions of NSTEMI and UA were also higher than those in Cullen’s study (8.7%) whilst non ACS cardiovascular-related conditions were 20.8% [14].

Different clinical characteristics and outcomes of patients between two hospitals

Since the patients with severe chest pain/symptoms would likely to present to EDs in GZ while those patients with mild chest pains/symptoms would visit clinics, so the baseline clinical characteristicsof patients in GZ were worse than those in HK. The patients were older, had lower proportion of NHYA class I and higher creatinine level, higherproportion of ST-segment depression, lower proportion of negative TnT and higher HEART scoreat ED presentation. Those factors have also been shown to be associated with 30-day and 6-month mortality. The same parameters have been verified to predict short- and long-term risks of death from ACS [1824]. Compared to HK, lower proportions of patients with risk factors were seen in GZ, whilst more patients with worse NHYA class were observed. This suggests that many chest pain patients in GZ did not have any knowledge of cardiac risk factors and were unaware of the presence of those risk factors, therefore the impact of those risk factors might be underestimated. Early detection and good control of risk factors for suspected cardiac chest pain patients may reduce mortality.
Furthermore, elevated serum creatinine level was an independent predictor for 30-day and 6-month mortality in our study.It has also been reported to be associated with worse outcomes for ACS and critically ill patients [18, 23]. Elevated serum creatinine can reflect vascular damage, renal impairment, endothelial dysfunction and impaired myocardial blood flow [2427]. A multinational registry study by Tang et al. showed that SBP could predict the 6-month mortality of all subsets of ACS. As SBP increases by 10 mmHg, the hazard ratio would decrease by 0.95 [27].
Several studies have reported that the HEART score is not only related to the severity of chest pain in EDs but also predicts the occurrence of clinical endpoints [2832]. Our study also demonstrated that the HEART score was positively associated with 30-day and 6-month mortality of suspected cardiac chest pain patients in the ED setting.
The dissimilarity of healthcare systems in the two cities is another reason for the different ED management. Limited capacity of hospital emergency care services, high out-of-pocket expenses with the need for up-front payment, prolonged discussions with the patient and families for both obtaining consent and pooling funds are likely to be major contributing factors for the long pre-hospital, in-hosptial delay and refused some expensive treatments [13, 32].
In ED chest pain pathways, guidelines recommend that an ECG should be recorded within 10 min and myocardial injury biomarkers should be measured as soon as possible in all suspected cardiac chest pain patients [4, 9]. The ED-ECG time and the proportion of patients having myocardial injury biomarkers measured in both hospitals met these guidelines.Myocardial injury biomarkers, such as troponin, CK and CK-MB are used to identify myocardial injury [33]. Many studies have shown that troponinis superior to CK and CK-MB as a biomarker for detection of myocardial injury [19, 20]. Therefore, troponin testing is recommended in most guidelines for its high sensitivity and specificity [17]. However in GZ, CK and CK-MB are still mainly used for the diagnosis of AMI and ACS due to their lower costs. High expenses with the need for up-front payment of troponin testing are likely to be a major contributing factor for the lower rate of use of troponin testing in GZ. The lower sensitivities and specificities of CK and CK-MB might contribute to the delayed diagnoses of AMI/ACS and later treatment of patients, possibly contributing to the higher early mortality in GZ. Except the mortaliy, readmissions after ACS are associated with higher long-term all-cause mortality [34].However, our study did not show the significant difference of 30-day and 6-month readmission rate in in HK and GZ. The reason was that the patients we enrolled were suspected cardiac chest pain patients instead of ACS.

Strengths and limitations

The strengths of this study include the fact it is the first comparison of outcomes in different healthcare systems in a similarly populated region of southern China, which effectively eliminates many confounding factors in any comparison. The current study also has some limitations, including the sample size of this study which met our precalculated size but may still be considered small by international standards. Secondly, patient risk factors (i.e. the past medical histories) may have been underestimated due to variations in history taking between the two centres. Thirdly, as a prospective observational study, propensity score with matching would attempt to reduce the bias due to confounding variables. However, this method requires large sample size. Also, the procedure only controls for observed variables, so any hidden bias due to latent variables may remain after matching.Logistic regression and Cox regression can meet the need of this study.

Conclusion

The 30-day and 6-month mortality of patients with suspected cardiac chest pain in Guangzhou were higher than in Hong Kong due to different baseline clinical characteristics of patients at ED presentation and different distributions of diagnoses which were associated with different healthcare systems. Serum creatinine and SBP were independent predictors of 30-day and 6-month mortality. Improved patient knowledge of risk factors along with early detection and good control of risk factors may lead to better outcomes for cardiac chest pain patients in southern China.

Funding

The Bureau of Science and Information Technology of Guangzhou Municipality (Grant No.2013 J4500009).
The Scientific Research Project of the Guangzhou Education Bureau (Grant No. 1201610645).
The Key Medical Disciplines and Specialties Program of Guangzhou.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethical approval was obtained from the joint Chinese University of Hong Kong-New Territories East Cluster (CUHK-NTEC) Clinical Research Ethics Committee in Hong Kong and the Institutional Review Board in Guangzhou to conduct a prospective observational study in patients with chest pain. Written informed consent was obtained from each patient after a verbal and written explanation of the study was provided. If patients were unable to give signed consent, written consent would obtained from relatives on behalf of patients. Patients were informed that they could withdraw from the study at any time.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Anhänge

Additional file

Additional file 1: Definition of HEART score [29]: There were five elements: history, ECG, age,risk factors and troponin in HEART score. Each variable was scored as 0, 1 or 2 points. Each patient will receive a score of 1-10. (DOCX 32 kb)
Literatur
1.
Zurück zum Zitat Amsterdam EA, Kirk JD, Bluemke DA, et al. American heart AssociationExercise, cardiac rehabilitation, and prevention Committee of the Council onClinical cardiology, council on cardiovascular nursing, and InterdisciplinaryCouncil on quality of care and outcomes research. Testing of low-risk patientspresenting to the emergency department with chest pain: a scientific statementfrom the American Heart Association. Circulation. 2010;122(17):1756–76. https://doi.org/10.1161/CIR.0b013e3181ec61df. CrossRefPubMedPubMedCentral Amsterdam EA, Kirk JD, Bluemke DA, et al. American heart AssociationExercise, cardiac rehabilitation, and prevention Committee of the Council onClinical cardiology, council on cardiovascular nursing, and InterdisciplinaryCouncil on quality of care and outcomes research. Testing of low-risk patientspresenting to the emergency department with chest pain: a scientific statementfrom the American Heart Association. Circulation. 2010;122(17):1756–76. https://​doi.​org/​10.​1161/​CIR.​0b013e3181ec61df​.​ CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Liu Y, Zhang B, Fu W, et al. A preliminary epidemiological study of the patient population visiting an urban ED in the republic of China. Am J Emerg Med. 1994;12(2):247–9.CrossRefPubMed Liu Y, Zhang B, Fu W, et al. A preliminary epidemiological study of the patient population visiting an urban ED in the republic of China. Am J Emerg Med. 1994;12(2):247–9.CrossRefPubMed
5.
Zurück zum Zitat Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into theACCF/AHA 2007 guidelines for the management ofpatients with unstable angina/non–ST-elevationmyocardial infarction: a report of the AmericanCollege of Cardiology Foundation/American HeartAssociation Task Force on Practice Guidelines. J AmCollCardiol. 2013;61(23):e179–347. https://doi.org/10.1016/j.jacc.2013.01.014.CrossRef Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into theACCF/AHA 2007 guidelines for the management ofpatients with unstable angina/non–ST-elevationmyocardial infarction: a report of the AmericanCollege of Cardiology Foundation/American HeartAssociation Task Force on Practice Guidelines. J AmCollCardiol. 2013;61(23):e179–347. https://​doi.​org/​10.​1016/​j.​jacc.​2013.​01.​014.CrossRef
10.
Zurück zum Zitat Fitzner KA, Coughlin S, Tomori C, Bennett CL. Health care in Hong Kong and mainland China: one country, two systems? Health Policy. 2000,53:147–55. Fitzner KA, Coughlin S, Tomori C, Bennett CL. Health care in Hong Kong and mainland China: one country, two systems? Health Policy. 2000,53:147–55.
14.
Zurück zum Zitat Cullen L, Greenslade J, Merollini K, et al. Cost and outcomes of assessing patients with chest pain in an Australian emergency department. Med J Aust. 2015;202(8):427–32.CrossRefPubMed Cullen L, Greenslade J, Merollini K, et al. Cost and outcomes of assessing patients with chest pain in an Australian emergency department. Med J Aust. 2015;202(8):427–32.CrossRefPubMed
15.
Zurück zum Zitat Soltani M, Mirzaei M, Amin A, et al. Predictors of adverse outcomes of patients with chest pain and primary diagnosis of non-cardiac pain at the time of discharge from emergency department: a 30-days prospective study. Ethiop J Health Sci. 2016;26(4):305–10.CrossRefPubMedPubMedCentral Soltani M, Mirzaei M, Amin A, et al. Predictors of adverse outcomes of patients with chest pain and primary diagnosis of non-cardiac pain at the time of discharge from emergency department: a 30-days prospective study. Ethiop J Health Sci. 2016;26(4):305–10.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat EA A, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the Management of Patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–228. https://doi.org/10.1016/jjacc2014.09.017.CrossRef EA A, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the Management of Patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–228. https://​doi.​org/​10.​1016/​jjacc2014.​09.​017.CrossRef
19.
Zurück zum Zitat Ooi SB, Lim YT, Lau TC, Chia BL, Pillai S, Liu T. Value oftroponin-T rapid assay, cardiac enzymes, electrocardiogram and history of chest pain in the initial diagnosis of myocardial infarction in the emergency department. Eur J Emerg Med. 2000;7(2):91–8.CrossRefPubMed Ooi SB, Lim YT, Lau TC, Chia BL, Pillai S, Liu T. Value oftroponin-T rapid assay, cardiac enzymes, electrocardiogram and history of chest pain in the initial diagnosis of myocardial infarction in the emergency department. Eur J Emerg Med. 2000;7(2):91–8.CrossRefPubMed
20.
Zurück zum Zitat Johnson PA, Goldman L, Sacks DB, et al. Cardiac troponin T as a marker for myocardial ischemia in patients seen at the emergency department for acute chest pain. Am Heart J. 1999;137(6):1137–44.CrossRefPubMed Johnson PA, Goldman L, Sacks DB, et al. Cardiac troponin T as a marker for myocardial ischemia in patients seen at the emergency department for acute chest pain. Am Heart J. 1999;137(6):1137–44.CrossRefPubMed
21.
Zurück zum Zitat Alexander KP, Newby LK, Cannon CP, et al. American Heart Association Council on Clinical Cardiology, Society of Geriatric Cardiology.Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2549–69. https://doi.org/10.1161/CIRCULATIONAHA.107.182616.CrossRefPubMed Alexander KP, Newby LK, Cannon CP, et al. American Heart Association Council on Clinical Cardiology, Society of Geriatric Cardiology.Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2549–69. https://​doi.​org/​10.​1161/​CIRCULATIONAHA.​107.​182616.CrossRefPubMed
24.
Zurück zum Zitat Zhao L, Wang L, Zhang Y. Elevated admission serum creatinine predicts poor myocardial blood flow and one-year mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. J Invasive Cardiol. 2009;21:493–8.PubMed Zhao L, Wang L, Zhang Y. Elevated admission serum creatinine predicts poor myocardial blood flow and one-year mortality in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. J Invasive Cardiol. 2009;21:493–8.PubMed
25.
Zurück zum Zitat Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPErandomized trial. Ann Intern Med. 2001;134:629–36.CrossRefPubMed Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPErandomized trial. Ann Intern Med. 2001;134:629–36.CrossRefPubMed
26.
Zurück zum Zitat Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: astatement from the American Heart Association councils on kidney in Cardiovascular disease, high blood pressure research, clinical Cardiology, and epidemiology and prevention. Hypertension. 2003;42:1050–65.CrossRefPubMed Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: astatement from the American Heart Association councils on kidney in Cardiovascular disease, high blood pressure research, clinical Cardiology, and epidemiology and prevention. Hypertension. 2003;42:1050–65.CrossRefPubMed
Metadaten
Titel
Comparison of outcomes in emergency department patients with suspected cardiac chest pain: two-centre prospective observational study in Southern China
verfasst von
Huilin Jiang
Yunmei Li
Junrong Mo
Xiaohui Chen
Min Li
Peiyi Lin
Kevin K. C. Hung
Timothy H. Rainer
Colin A. Graham
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
BMC Cardiovascular Disorders / Ausgabe 1/2018
Elektronische ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-018-0814-4

Weitere Artikel der Ausgabe 1/2018

BMC Cardiovascular Disorders 1/2018 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.